A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer

Chao H. Huang, Jo A. Wick, Gurusingham Sitta Sittampalam, Victor Sanjit Nirmalanandhan, Apar Kishor P Ganti, Prakash C. Neupane, Stephen K. Williamson, Andrew K. Godwin, Sarah Schmitt, Nora J. Smart, Sarah Spencer, Peter J. Van Veldhuizen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Small-cell lung cancer (SCLC), a variant of lung cancer marked by early metastases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for patients with extensive stage (EX-SCLC). Detection of circulating tumor cells (CTCs) is a novel laboratory technique currently in use to determine response to therapy and to predict prognosis in breast, colorectal, and prostate cancer. We initiated a pilot study to analyze the role of CTCs as a biomarker of response and relapse in patients with EX-SCLC. Methods: We collected blood samples from chemotherapy naïve patients with EX-SCLC prior to initiation of therapy, after completion of systemic therapy, and follow-up every 6-8 weeks and at relapse. The number of CTCs was determined using the cell search system in a central laboratory. The study was conducted in four different sites, and it was reviewed and approved by respective research review committees and IRBs. Results: We enrolled 26 patients with EX-SCLC, 1 was excluded due to ineligibility, all were treated with platinum and etoposide. We observed partial response in 16 patients, stable disease in 3 patients, 1 patient with disease progression, and 6 patients were not assessed (5 deceased, 1 not available). The overall median number of CTCs in 24 patients measured at baseline and post-tx was 75 (range 0-3430) and 2 (range 0-526), respectively. A significant reduction in CTCs from baseline to post-treatment was identified for 15 subjects; the median reduction was 97.4% (range -100 to +100%, p < 0.001). Higher baseline CTCs and percentage change in post-treatment CTCs were associated with decreased survival. Conclusion: We demonstrated that it is feasible to detect CTCs in EX-SCLC. If validated in other prospective studies, CTCs could be a useful biomarker in the management of EX-SCLC by predicting patients' clinical responses to therapy.

Original languageEnglish (US)
Article number271
JournalFrontiers in Oncology
Volume4
Issue numberOCT
DOIs
StatePublished - 2014

Fingerprint

Circulating Neoplastic Cells
Small Cell Lung Carcinoma
Tumor Biomarkers
Multicenter Studies
Therapeutics
Lung Neoplasms
Biomarkers
Recurrence
Survival
Research Ethics Committees
Etoposide
Advisory Committees
Platinum
Disease Progression
Colorectal Neoplasms
Prostatic Neoplasms
Prospective Studies
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • Biomarkers
  • Circulating tumor cells
  • Extensive stage
  • Prognosis
  • Small-cell lung carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer. / Huang, Chao H.; Wick, Jo A.; Sittampalam, Gurusingham Sitta; Nirmalanandhan, Victor Sanjit; Ganti, Apar Kishor P; Neupane, Prakash C.; Williamson, Stephen K.; Godwin, Andrew K.; Schmitt, Sarah; Smart, Nora J.; Spencer, Sarah; Van Veldhuizen, Peter J.

In: Frontiers in Oncology, Vol. 4, No. OCT, 271, 2014.

Research output: Contribution to journalArticle

Huang, CH, Wick, JA, Sittampalam, GS, Nirmalanandhan, VS, Ganti, AKP, Neupane, PC, Williamson, SK, Godwin, AK, Schmitt, S, Smart, NJ, Spencer, S & Van Veldhuizen, PJ 2014, 'A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer', Frontiers in Oncology, vol. 4, no. OCT, 271. https://doi.org/10.3389/fonc.2014.00271
Huang, Chao H. ; Wick, Jo A. ; Sittampalam, Gurusingham Sitta ; Nirmalanandhan, Victor Sanjit ; Ganti, Apar Kishor P ; Neupane, Prakash C. ; Williamson, Stephen K. ; Godwin, Andrew K. ; Schmitt, Sarah ; Smart, Nora J. ; Spencer, Sarah ; Van Veldhuizen, Peter J. / A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer. In: Frontiers in Oncology. 2014 ; Vol. 4, No. OCT.
@article{da881342c48f4264830db88cd1556fb9,
title = "A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer",
abstract = "Background: Small-cell lung cancer (SCLC), a variant of lung cancer marked by early metastases, accounts for 13{\%} of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for patients with extensive stage (EX-SCLC). Detection of circulating tumor cells (CTCs) is a novel laboratory technique currently in use to determine response to therapy and to predict prognosis in breast, colorectal, and prostate cancer. We initiated a pilot study to analyze the role of CTCs as a biomarker of response and relapse in patients with EX-SCLC. Methods: We collected blood samples from chemotherapy na{\"i}ve patients with EX-SCLC prior to initiation of therapy, after completion of systemic therapy, and follow-up every 6-8 weeks and at relapse. The number of CTCs was determined using the cell search system in a central laboratory. The study was conducted in four different sites, and it was reviewed and approved by respective research review committees and IRBs. Results: We enrolled 26 patients with EX-SCLC, 1 was excluded due to ineligibility, all were treated with platinum and etoposide. We observed partial response in 16 patients, stable disease in 3 patients, 1 patient with disease progression, and 6 patients were not assessed (5 deceased, 1 not available). The overall median number of CTCs in 24 patients measured at baseline and post-tx was 75 (range 0-3430) and 2 (range 0-526), respectively. A significant reduction in CTCs from baseline to post-treatment was identified for 15 subjects; the median reduction was 97.4{\%} (range -100 to +100{\%}, p < 0.001). Higher baseline CTCs and percentage change in post-treatment CTCs were associated with decreased survival. Conclusion: We demonstrated that it is feasible to detect CTCs in EX-SCLC. If validated in other prospective studies, CTCs could be a useful biomarker in the management of EX-SCLC by predicting patients' clinical responses to therapy.",
keywords = "Biomarkers, Circulating tumor cells, Extensive stage, Prognosis, Small-cell lung carcinoma",
author = "Huang, {Chao H.} and Wick, {Jo A.} and Sittampalam, {Gurusingham Sitta} and Nirmalanandhan, {Victor Sanjit} and Ganti, {Apar Kishor P} and Neupane, {Prakash C.} and Williamson, {Stephen K.} and Godwin, {Andrew K.} and Sarah Schmitt and Smart, {Nora J.} and Sarah Spencer and {Van Veldhuizen}, {Peter J.}",
year = "2014",
doi = "10.3389/fonc.2014.00271",
language = "English (US)",
volume = "4",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "OCT",

}

TY - JOUR

T1 - A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer

AU - Huang, Chao H.

AU - Wick, Jo A.

AU - Sittampalam, Gurusingham Sitta

AU - Nirmalanandhan, Victor Sanjit

AU - Ganti, Apar Kishor P

AU - Neupane, Prakash C.

AU - Williamson, Stephen K.

AU - Godwin, Andrew K.

AU - Schmitt, Sarah

AU - Smart, Nora J.

AU - Spencer, Sarah

AU - Van Veldhuizen, Peter J.

PY - 2014

Y1 - 2014

N2 - Background: Small-cell lung cancer (SCLC), a variant of lung cancer marked by early metastases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for patients with extensive stage (EX-SCLC). Detection of circulating tumor cells (CTCs) is a novel laboratory technique currently in use to determine response to therapy and to predict prognosis in breast, colorectal, and prostate cancer. We initiated a pilot study to analyze the role of CTCs as a biomarker of response and relapse in patients with EX-SCLC. Methods: We collected blood samples from chemotherapy naïve patients with EX-SCLC prior to initiation of therapy, after completion of systemic therapy, and follow-up every 6-8 weeks and at relapse. The number of CTCs was determined using the cell search system in a central laboratory. The study was conducted in four different sites, and it was reviewed and approved by respective research review committees and IRBs. Results: We enrolled 26 patients with EX-SCLC, 1 was excluded due to ineligibility, all were treated with platinum and etoposide. We observed partial response in 16 patients, stable disease in 3 patients, 1 patient with disease progression, and 6 patients were not assessed (5 deceased, 1 not available). The overall median number of CTCs in 24 patients measured at baseline and post-tx was 75 (range 0-3430) and 2 (range 0-526), respectively. A significant reduction in CTCs from baseline to post-treatment was identified for 15 subjects; the median reduction was 97.4% (range -100 to +100%, p < 0.001). Higher baseline CTCs and percentage change in post-treatment CTCs were associated with decreased survival. Conclusion: We demonstrated that it is feasible to detect CTCs in EX-SCLC. If validated in other prospective studies, CTCs could be a useful biomarker in the management of EX-SCLC by predicting patients' clinical responses to therapy.

AB - Background: Small-cell lung cancer (SCLC), a variant of lung cancer marked by early metastases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for patients with extensive stage (EX-SCLC). Detection of circulating tumor cells (CTCs) is a novel laboratory technique currently in use to determine response to therapy and to predict prognosis in breast, colorectal, and prostate cancer. We initiated a pilot study to analyze the role of CTCs as a biomarker of response and relapse in patients with EX-SCLC. Methods: We collected blood samples from chemotherapy naïve patients with EX-SCLC prior to initiation of therapy, after completion of systemic therapy, and follow-up every 6-8 weeks and at relapse. The number of CTCs was determined using the cell search system in a central laboratory. The study was conducted in four different sites, and it was reviewed and approved by respective research review committees and IRBs. Results: We enrolled 26 patients with EX-SCLC, 1 was excluded due to ineligibility, all were treated with platinum and etoposide. We observed partial response in 16 patients, stable disease in 3 patients, 1 patient with disease progression, and 6 patients were not assessed (5 deceased, 1 not available). The overall median number of CTCs in 24 patients measured at baseline and post-tx was 75 (range 0-3430) and 2 (range 0-526), respectively. A significant reduction in CTCs from baseline to post-treatment was identified for 15 subjects; the median reduction was 97.4% (range -100 to +100%, p < 0.001). Higher baseline CTCs and percentage change in post-treatment CTCs were associated with decreased survival. Conclusion: We demonstrated that it is feasible to detect CTCs in EX-SCLC. If validated in other prospective studies, CTCs could be a useful biomarker in the management of EX-SCLC by predicting patients' clinical responses to therapy.

KW - Biomarkers

KW - Circulating tumor cells

KW - Extensive stage

KW - Prognosis

KW - Small-cell lung carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84987958770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987958770&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00271

DO - 10.3389/fonc.2014.00271

M3 - Article

VL - 4

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - OCT

M1 - 271

ER -